Synovial Fibroblast 1: Secretion response of primary human synovial fibroblast samples from one healthy and one rheumatoid arthritis donor to a panel of 10 stimuli and 10 small molecule inhibitors - Dataset (ID:20233)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
N2586 | Ruxolitinib | 0.3 | uM | IGF-I | 100 | ug/mL | 3 | IL-17 | 46.0 | 69 | |
N2586 | Tofacitinib | 0.3 | uM | IGF-I | 100 | ug/mL | 3 | IL-17 | 42.5 | 82 | |
N2586 | IKK16 | 2.0 | uM | IGF-I | 100 | ug/mL | 3 | IL-17 | 47.0 | 50 | |
N2586 | 3 | IL-17 | 54.0 | 65 | |||||||
RA2159 | EGF | 100 | ng/mL | 3 | IL-17 | 40.5 | 60 | ||||
RA2159 | PD184352 | 0.1 | uM | EGF | 100 | ng/mL | 3 | IL-17 | 41.0 | 53 | |
RA2159 | Lestaurtinib | 0.3 | uM | EGF | 100 | ng/mL | 3 | IL-17 | 44.5 | 68 | |
RA2159 | Ruxolitinib | 0.3 | uM | EGF | 100 | ng/mL | 3 | IL-17 | 45.5 | 34 | |
RA2159 | Tofacitinib | 0.3 | uM | EGF | 100 | ng/mL | 3 | IL-17 | 37.0 | 59 | |
RA2159 | IKK16 | 2.0 | uM | EGF | 100 | ng/mL | 3 | IL-17 | 37.5 | 52 | |
RA2159 | JNK-IN-11 | 0.3 | uM | 3 | IL-17 | 41.0 | 82 | ||||
N2586 | EGF | 100 | ng/mL | 3 | IL-17 | 47.0 | 69 | ||||
N2586 | PD184352 | 0.1 | uM | EGF | 100 | ng/mL | 3 | IL-17 | 47.0 | 65 | |
N2586 | Lestaurtinib | 0.3 | uM | EGF | 100 | ng/mL | 3 | IL-17 | 47.0 | 61 | |
N2586 | Ruxolitinib | 0.3 | uM | EGF | 100 | ng/mL | 3 | IL-17 | 43.0 | 68 | |
N2586 | Tofacitinib | 0.3 | uM | EGF | 100 | ng/mL | 3 | IL-17 | 41.0 | 67 | |
N2586 | IKK16 | 2.0 | uM | EGF | 100 | ng/mL | 3 | IL-17 | 36.0 | 52 | |
N2586 | JNK-IN-11 | 0.3 | uM | 3 | IL-17 | 44.5 | 60 | ||||
RA2159 | 3 | IL-17 | 46.5 | 74 | |||||||
RA2159 | PD184352 | 0.1 | uM | 3 | IL-17 | 49.0 | 59 | ||||
RA2159 | Lestaurtinib | 0.3 | uM | 3 | IL-17 | 41.0 | 55 | ||||
RA2159 | Ruxolitinib | 0.3 | uM | 3 | IL-17 | 44.0 | 49 | ||||
RA2159 | Tofacitinib | 0.3 | uM | 3 | IL-17 | 48.0 | 74 | ||||
RA2159 | IKK16 | 2.0 | uM | 3 | IL-17 | 44.0 | 68 | ||||
RA2159 | JNK-IN-8 | 3.0 | uM | 3 | IL-17 | 41.5 | 58 |